Rite Aid releases diabetic health guide, leads effort to raise money for research
CAMP HILL, Pa. Rite Aid on Tuesday announced it would make available a 16-page Diabetes Guide, developed in partnership with the American Diabetes Association, at its stores in preparation for National Diabetes Month next month.
Also, from now through November, Rite Aid pharmacists will lead customers in 80 American Diabetes Association-sponsored walks across the country to raise money to help find a cure for diabetes.
In November, all Rite Aid stores will sell $1 American Diabetes Association pin-ups, with all proceeds going directly to the American Diabetes Association for diabetes research, information and advocacy initiatives. And on Nov. 11 and 13, select Rite Aid stores will host Diabetes Solutions Days events, where patients can receive free blood pressure screenings, personal consultations with a Rite Aid pharmacist on managing diabetes and diabetic product samples. Patients can also enter for a chance to win a $50 gift card.
Through its partnership with dLife, Rite Aid has created a free online Rite for Diabetes program. Membership is free and once enrolled, patients receive a free e-newsletter and savings, as well as lifestyle advice including access to Personal Menu Solutions, an online tool to help plan, track and maintain daily meals and exercise.
Rite Aid reports cash dividend payout for preferred stock
CAMP HILL, Pa. Rite Aid on Monday declared a cash dividend of $0.4049 per share on its 5.5 percent Series I Mandatory Convertible Preferred Stock for the period commencing on Aug. 1, 2008 through Nov. 16, 2008.
The dividend is payable on Nov. 17, 2008 to shareholders of record as of Oct. 15, 2008, the company stated.
Deciphera, Lilly partner to test compounds in treatment of cancer
INDIANAPOLIS Eli Lilly and Deciphera Pharmaceuticals said Friday they would collaborate to investigate a group of Deciphera compounds as a potential cancer treatment.
The companies said they would investigate Deciphera’s preclinical B-Raf kinase inhibitors as cancer treatments, combining Deciphera’s drug-discovery resources and Lilly’s drug discovery, development and commercialization resources.
“This collaboration is further evidence of Lilly’s ongoing commitment to oncology research,” Lilly vice president for discovery research and clinical investigation Dr. William Chin said. “We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for cancer patients.”
As part of the deal, Lilly will obtain exclusive worldwide rights to any products developed as part of the collaboration, while Deciphera will receive an upfront payment and research funding, as well as up to $130 million in development, regulatory and sales milestone payments.